|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date27 Feb 2008 |
Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis
The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.
An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis
The purpose of this study is to assess the preliminary efficacy and safety of KPL-914 treatment in participants with recurrent pericarditis.
100 Clinical Results associated with Kiniksa Pharmaceuticals (UK) Ltd.
0 Patents (Medical) associated with Kiniksa Pharmaceuticals (UK) Ltd.
100 Deals associated with Kiniksa Pharmaceuticals (UK) Ltd.
100 Translational Medicine associated with Kiniksa Pharmaceuticals (UK) Ltd.